Business
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the
About this update from Polaryx Therapeutics, Inc.
[{"type":"text","content":"Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug candidate PLX-200\nPARAMUS, NJ, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it will be presenting a late-breaking abstract on new data for PLX-200, an investigational therapy for the treatment of Krabbe disease (globoid cell leukodystrophy) at the 22nd Annual WORLDSymposium™, held February 2-6, 2026 in San Diego, Calif. These data support the continued advancement on progressing the launch of the SOTERIA trial, a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of PLX-200, in CLN2, CLN3, Krabbe disease, and Sandhoff disease. “These data, which we were honored to learn was accepted as a late-breaking abstract the prestigious WORLDSymposium™ 2026, form the foundation of our work on PLX-200 in Krabbe disease,” said Lisa Bollinger, M.D., Polaryx Therapeutics Chief Medical Officer. “As one of the four indications in our Phase 2 SOTERIA basket trial, we continue to reinforce our commitment to addressing significant unmet needs across lysosomal storage disorders and are excited about the ongoing preparations of SOTERIA.” The SOTERIA trial represents a flexible and resource‑efficient opportunity to validate PLX‑200’s preclinical science across multiple LSDs while gathering data important in planning PLX‑200’s future development pathway. Polaryx received a safe to proceed letter in October 2025 from the FDA and is actively planning with its contract research organization (CRO) to initiate the trial in the first half of 2026. Shrijay Vijayan, Ph.D., MBA, Polaryx Therapeutics Chief Scientific and Business Development Officer, will present preclinical findings in an oral presentation on PLX-200 in a mouse model of Krabbe disease. The presentation details are as follows: Title: Gemfibrozil attenuates disease progression in mouse model of Krabbe disease: Basis for the initiation of SOTERIA, a phase 2 clinical trial of PLX-200 (newly formulated gemfibrozil) in lysosomal disordersPresentation Type: OralPresenter: Shrij...